Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference newsletter


  Breast Cancer

  Free Subscription


05.10.2020

1 AJR Am J Roentgenol
2 Ann Oncol
6 Ann Surg Oncol
6 Anticancer Res
8 BMC Cancer
2 BMJ
5 Breast Cancer
2 Breast Cancer (Dove Med Press)
11 Breast Cancer Res
21 Breast Cancer Res Treat
1 Breast J
1 Cancer
1 Cancer Cell
4 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
5 Cancer Res
1 Clin Breast Cancer
6 Clin Cancer Res
1 Clin Med Insights Oncol
1 Eur J Cancer
4 Eur Radiol
1 Exp Cell Res
1 Gene
3 Int J Cancer
1 J Clin Invest
4 J Natl Cancer Inst
2 J Surg Oncol
2 Lancet Oncol
2 Oncogene
3 Oncol Rep
1 Oncology
1 PLoS Med
4 PLoS One
1 Proc Natl Acad Sci U S A
3 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. CHUNG H, Sun J, Leung JWT
    Breast Cancer Skip Metastases: Frequency, Associated Tumor Characteristics, and Role of Staging Nodal Ultrasound in Detection.
    AJR Am J Roentgenol. 2020 Sep 30. doi: 10.2214/AJR.20.24371.
    PubMed         Abstract available


    Ann Oncol

  2. GRINDA T, Delaloge S
    Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?
    Ann Oncol. 2020 Sep 29. pii: S0923-7534(20)42468.
    PubMed        

  3. CARDOSO F, Paluch-Shimon S, Senkus E, Curigliano G, et al
    5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)(dagger).
    Ann Oncol. 2020 Sep 23. pii: S0923-7534(20)42460.
    PubMed        


    Ann Surg Oncol

  4. BERGSTROM C, Pence C, Berg J, Partain N, et al
    Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations.
    Ann Surg Oncol. 2020 Sep 29. pii: 10.1245/s10434-020-09158.
    PubMed         Abstract available

  5. PARK KU, Weiss A, Rosso K, Yi M, et al
    Use of Mammographic Measurements to Predict Complications After Nipple-Sparing Mastectomy in BRCA Mutation Carriers.
    Ann Surg Oncol. 2020;27:367-372.
    PubMed         Abstract available

  6. GROVA MM, Strassle PD, Navajas EE, Gallagher KK, et al
    The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer.
    Ann Surg Oncol. 2020 Sep 24. pii: 10.1245/s10434-020-09152.
    PubMed         Abstract available

  7. CAO L, Xu C, Cai G, Qi WX, et al
    How Does the Interval Between Completion of Adjuvant Chemotherapy and Initiation of Radiotherapy Impact Clinical Outcomes in Operable Breast Cancer Patients?
    Ann Surg Oncol. 2020 Sep 24. pii: 10.1245/s10434-020-09026.
    PubMed         Abstract available

  8. METCALFE KA, Eisen A, Poll A, Candib A, et al
    Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study.
    Ann Surg Oncol. 2020 Sep 28. pii: 10.1245/s10434-020-09160.
    PubMed         Abstract available

  9. BERGSTROM CP, Pence C, Syed S
    ASO Author Reflections: Clinical Correlates of Moderate-Penetrance Genes in Breast Cancer.
    Ann Surg Oncol. 2020 Oct 1. pii: 10.1245/s10434-020-09187.
    PubMed        


    Anticancer Res

  10. WAZIR U, Mokbel K
    De-escalation of Axillary Surgery in the Neoadjuvant Chemotherapy (NACT) Setting for Breast Cancer: Is it Oncologically Safe?
    Anticancer Res. 2020;40:5351-5354.
    PubMed         Abstract available

  11. YENILMEZ EN, Genc D, Farooqi AA, Tunoglu S, et al
    Mesenchymal Stem Cells Combined With IFNgamma Induce Apoptosis of Breast Cancer Cells Partially Through TRAIL.
    Anticancer Res. 2020;40:5641-5647.
    PubMed         Abstract available

  12. LI CL, Huang CW, Ko CJ, Fang SY, et al
    Curcumol Suppresses Triple-negative Breast Cancer Metastasis by Attenuating Anoikis Resistance via Inhibition of Skp2-mediated Transcriptional Addiction.
    Anticancer Res. 2020;40:5529-5538.
    PubMed         Abstract available

  13. MARGAN MM, Cimpean AM, Ceausu AR, Raica M, et al
    Differential Expression of E-Cadherin and P-Cadherin in Breast Cancer Molecular Subtypes.
    Anticancer Res. 2020;40:5557-5566.
    PubMed         Abstract available

  14. SHINDEN Y, Nagata A, Nomoto Y, Saho H, et al
    Surgical Resection With Pedicled Rotation Flap for Post-mastectomy Locoregional Breast Cancer Recurrence.
    Anticancer Res. 2020;40:5739-5742.
    PubMed         Abstract available

  15. SCATOZZA F, D'Amore A, Fontanella RA, DE Cesaris P, et al
    Toll-Iike Receptor-3 Activation Enhances Malignant Traits in Human Breast Cancer Cells Through Hypoxia-inducible Factor-1alpha.
    Anticancer Res. 2020;40:5379-5391.
    PubMed         Abstract available


    BMC Cancer

  16. CULBERTSON MG, Bennett K, Kelly CM, Sharp L, et al
    The psychosocial determinants of quality of life in breast cancer survivors: a scoping review.
    BMC Cancer. 2020;20:948.
    PubMed         Abstract available

  17. LEE J, Jung JH, Kim WW, Park CS, et al
    Efficacy of breast MRI for surgical decision in patients with breast cancer: ductal carcinoma in situ versus invasive ductal carcinoma.
    BMC Cancer. 2020;20:934.
    PubMed         Abstract available

  18. XIA L, Li F, Qiu J, Feng Z, et al
    Oncogenic miR-20b-5p contributes to malignant behaviors of breast cancer stem cells by bidirectionally regulating CCND1 and E2F1.
    BMC Cancer. 2020;20:949.
    PubMed         Abstract available

  19. FUJITA M, Imadome K, Somasundaram V, Kawanishi M, et al
    Metabolic characterization of aggressive breast cancer cells exhibiting invasive phenotype: impact of non-cytotoxic doses of 2-DG on diminishing invasiveness.
    BMC Cancer. 2020;20:929.
    PubMed         Abstract available

  20. MANOHARAN V, Karunanayake EH, Tennekoon KH, De Silva S, et al
    Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
    BMC Cancer. 2020;20:72.
    PubMed         Abstract available

  21. HA JH, Hong KY, Lee HB, Moon HG, et al
    Oncologic outcomes after immediate breast reconstruction following mastectomy: comparison of implant and flap using propensity score matching.
    BMC Cancer. 2020;20:78.
    PubMed         Abstract available

  22. AKAHANE T, Kanomata N, Harada O, Yamashita T, et al
    Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
    BMC Cancer. 2020;20:944.
    PubMed         Abstract available

  23. INARI H, Teruya N, Kishi M, Horii R, et al
    Clinicopathological features of breast cancer patients with internal mammary and/or supraclavicular lymph node recurrence without distant metastasis.
    BMC Cancer. 2020;20:932.
    PubMed         Abstract available


    BMJ

  24. THORNTON H
    Blatant disregard to proper consent continues in screening programmes.
    BMJ. 2020;370:m3592.
    PubMed        

  25. GRIFFIN S
    Pause in breast cancer screening is opportunity to re-evaluate programme, says critic.
    BMJ. 2020;371:m3810.
    PubMed        


    Breast Cancer

  26. BANDEIRA G, Rocha K, Lazar M, Ezquina S, et al
    Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer.
    Breast Cancer. 2020 Sep 28. pii: 10.1007/s12282-020-01165.
    PubMed         Abstract available

  27. VURAL V, Yilmaz OC
    The Turkish SentiMAG feasibility trial: preliminary results.
    Breast Cancer. 2020;27:261-265.
    PubMed         Abstract available

  28. YOU C, Zhang Y, Gu Y, Xiao Q, et al
    Comparison of the diagnostic performance of synthesized two-dimensional mammography and full-field digital mammography alone or in combination with digital breast tomosynthesis.
    Breast Cancer. 2020;27:47-53.
    PubMed         Abstract available

  29. NAGURA N, Hayashi N, Takei J, Yoshida A, et al
    Breast reconstruction after risk-reducing mastectomy in BRCA mutation carriers.
    Breast Cancer. 2020;27:70-76.
    PubMed         Abstract available

  30. IZUMORI A, Kokubu Y, Sato K, Gomi N, et al
    Usefulness of second-look ultrasonography using anatomical breast structures as indicators for magnetic resonance imaging-detected breast abnormalities.
    Breast Cancer. 2020;27:129-139.
    PubMed         Abstract available


    Breast Cancer (Dove Med Press)

  31. MANSOURI S, Alhadidi T, Ben Azouz M
    Breast Cancer Detection Using Low-Frequency Bioimpedance Device.
    Breast Cancer (Dove Med Press). 2020;12:109-116.
    PubMed         Abstract available

  32. ZELEKE ALEM A, Gebeye Zeleke E, Akalu TY
    Time to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study.
    Breast Cancer (Dove Med Press). 2020;12:97-108.
    PubMed         Abstract available


    Breast Cancer Res

  33. WANG D, Xiao F, Feng Z, Li M, et al
    Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence.
    Breast Cancer Res. 2020;22:103.
    PubMed         Abstract available

  34. BRENTNALL AR, Warren R, Harkness EF, Astley SM, et al
    Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.
    Breast Cancer Res. 2020;22:101.
    PubMed         Abstract available

  35. SIRISENA N, Biswas K, Sullivan T, Stauffer S, et al
    Functional evaluation of five BRCA2 unclassified variants identified in a Sri Lankan cohort with inherited cancer syndromes using a mouse embryonic stem cell-based assay.
    Breast Cancer Res. 2020;22:43.
    PubMed         Abstract available

  36. BURKHOLDER A, Akrobetu D, Pandiri AR, Ton K, et al
    Investigation of the adolescent female breast transcriptome and the impact of obesity.
    Breast Cancer Res. 2020;22:44.
    PubMed         Abstract available

  37. KIM M, Chung YR, Kim HJ, Woo JW, et al
    Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Breast Cancer Res. 2020;22:32.
    PubMed         Abstract available

  38. TANK A, Peterson HM, Pera V, Tabassum S, et al
    Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.
    Breast Cancer Res. 2020;22:29.
    PubMed         Abstract available

  39. LI M, Pan M, You C, Zhao F, et al
    MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.
    Breast Cancer Res. 2020;22:26.
    PubMed         Abstract available

  40. LLANOS AAM, Lin Y, Chen W, Yao S, et al
    Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype.
    Breast Cancer Res. 2020;22:18.
    PubMed         Abstract available

  41. OCANA A, Amir E, Pandiella A
    HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.
    Breast Cancer Res. 2020;22:15.
    PubMed         Abstract available

  42. JABER MI, Song B, Taylor C, Vaske CJ, et al
    A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.
    Breast Cancer Res. 2020;22:12.
    PubMed         Abstract available

  43. YOOSUF N, Navarro JF, Salmen F, Stahl PL, et al
    Identification and transfer of spatial transcriptomics signatures for cancer diagnosis.
    Breast Cancer Res. 2020;22:6.
    PubMed         Abstract available


    Breast Cancer Res Treat

  44. KOPPARTHY P, Daily K
    A case for Tamoxifen with ovarian function suppression.
    Breast Cancer Res Treat. 2020;183:241-242.
    PubMed        

  45. HERNANZ F
    Comments on patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer.
    Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05945.
    PubMed        

  46. VAN RAEMDONCK E, Floris G, Berteloot P, Laenen A, et al
    Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Sep 27. pii: 10.1007/s10549-020-05935.
    PubMed         Abstract available

  47. JIANG YZ, Ge LP, Jin X, Fan L, et al
    Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.
    Breast Cancer Res Treat. 2020 Sep 25. pii: 10.1007/s10549-020-05940.
    PubMed         Abstract available

  48. FUNK A, Heil J, Harcos A, Gomez C, et al
    Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery.
    Breast Cancer Res Treat. 2020;179:425-433.
    PubMed         Abstract available

  49. MERRILL NM, Lachacz EJ, Vandecan NM, Ulintz PJ, et al
    Molecular determinants of drug response in TNBC cell lines.
    Breast Cancer Res Treat. 2020;179:337-347.
    PubMed         Abstract available

  50. MOHAMADZADE Z, Mahjoubi F, Soltani BM
    Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer.
    Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05937.
    PubMed         Abstract available

  51. ZAHL PH, Kristiansen IS
    Re: Stage-specific survival has improved for young breast cancer patients since 2000: but not equally?
    Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05941.
    PubMed        

  52. ABDEL-RAZEQ H, Edaily S, Iweir S, Salam M, et al
    Effect of level of hormone-receptor expression on treatment outcomes of "triple-positive" early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05942.
    PubMed         Abstract available

  53. KYKER-SNOWMAN K, Hughes RM, Yankaskas CL, Cravero K, et al
    TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties.
    Breast Cancer Res Treat. 2020;179:631-642.
    PubMed         Abstract available

  54. BROWNE JL, Casas L, Santandreu G, Rodriguez I, et al
    Breast density measured volumetrically in a clinical environment: cross-sectional study with photon counting technology.
    Breast Cancer Res Treat. 2020;179:755-762.
    PubMed         Abstract available

  55. LOOK HONG N, Wright FC, Semple M, Nicolae AM, et al
    Results of a phase I, non-randomized study evaluating a Magnetic Occult Lesion Localization Instrument (MOLLI) for excision of non-palpable breast lesions.
    Breast Cancer Res Treat. 2020;179:671-676.
    PubMed         Abstract available

  56. LAI V, Hajjaj O, Le D, Shokoohi A, et al
    Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? : Time from Neoadjuvant Chemotherapy to Surgery.
    Breast Cancer Res Treat. 2020 Oct 1. pii: 10.1007/s10549-020-05894.
    PubMed         Abstract available

  57. YAN S, Dey P, Ziegler Y, Jiao X, et al
    Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.
    Breast Cancer Res Treat. 2020 Oct 1. pii: 10.1007/s10549-020-05948.
    PubMed         Abstract available

  58. BERRY DL, Blonquist TM, Halpenny B, Hong F, et al
    The Jacki Jacket after mastectomy with reconstruction: a randomized pilot study.
    Breast Cancer Res Treat. 2020;179:377-385.
    PubMed         Abstract available

  59. MEIER DR, Girtman MA, Lofgren KA, Kenny PA, et al
    Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice.
    Breast Cancer Res Treat. 2020;179:653-660.
    PubMed         Abstract available

  60. MULLOOLY M, Withrow DR, Curtis RE, Fan S, et al
    Association of lifestyle and clinical characteristics with receipt of radiotherapy treatment among women diagnosed with DCIS in the NIH-AARP Diet and Health Study.
    Breast Cancer Res Treat. 2020;179:445-457.
    PubMed         Abstract available

  61. PARK JW, Han K, Shin DW, Yeo Y, et al
    Obesity and breast cancer risk for pre- and postmenopausal women among over 6 million Korean women.
    Breast Cancer Res Treat. 2020 Oct 3. pii: 10.1007/s10549-020-05952.
    PubMed         Abstract available

  62. NEALON KP, Sobti N, Gadd M, Specht M, et al
    Assessing the additional surgical risk of contralateral prophylactic mastectomy and immediate breast implant reconstruction.
    Breast Cancer Res Treat. 2020;179:255-265.
    PubMed         Abstract available

  63. KOELMEYER LA, Moloney E, Boyages J, Sherman KA, et al
    Prospective surveillance model in the home for breast cancer-related lymphoedema: a feasibility study.
    Breast Cancer Res Treat. 2020 Oct 1. pii: 10.1007/s10549-020-05953.
    PubMed         Abstract available

  64. MITRA D, Bhattacharyya S, Alam N, Sen S, et al
    Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
    Breast Cancer Res Treat. 2020;179:359-370.
    PubMed         Abstract available


    Breast J

  65. KAPADIA S, Gudiwada SP, Kaji AH, Chlebowski RT, et al
    Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?
    Breast J. 2020 Oct 1. doi: 10.1111/tbj.14068.
    PubMed         Abstract available


    Cancer

  66. GREENE N, Malone J, Adams MA, Dean LT, et al
    "This is some mess right here": Exploring interactions between Black sexual minority women and health care providers for breast cancer screening and care.
    Cancer. 2020 Sep 29. doi: 10.1002/cncr.33219.
    PubMed         Abstract available


    Cancer Cell

  67. ROS S, Wright AJ, D'Santos P, Hu DE, et al
    Metabolic Imaging Detects Resistance to PI3Kalpha Inhibition Mediated by Persistent FOXM1 Expression in ER(+) Breast Cancer.
    Cancer Cell. 2020 Sep 14. pii: S1535-6108(20)30427.
    PubMed         Abstract available


    Cancer Epidemiol Biomarkers Prev

  68. COLLIN LJ, Gaglioti AH, Beyer KMM, Zhou Y, et al
    Neighborhood-level redlining and lending bias are associated with breast cancer mortality in a large and diverse metropolitan area.
    Cancer Epidemiol Biomarkers Prev. 2020 Oct 2. pii: 1055-9965.EPI-20-1038.
    PubMed         Abstract available

  69. RAUF F, Anderson KS, LaBaer J
    Autoantibodies in early detection of breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2020 Sep 29. pii: 1055-9965.EPI-20-0331.
    PubMed         Abstract available

  70. HOUGHTON LC, Howland RE, Wei Y, Ma X, et al
    The steroid metabolome and breast cancer risk in women with a family history of breast cancer: the novel role of adrenal androgens and glucocorticoids.
    Cancer Epidemiol Biomarkers Prev. 2020 Sep 30. pii: 1055-9965.EPI-20-0471.
    PubMed         Abstract available

  71. PHILLIPS SM, Welch WA, Fanning J, Santa-Maria CA, et al
    Daily Physical Activity and Symptom Reporting in Breast Cancer Patients Undergoing Chemotherapy: An Intensive Longitudinal Examination.
    Cancer Epidemiol Biomarkers Prev. 2020 Sep 29. pii: 1055-9965.EPI-20-0659.
    PubMed         Abstract available


    Cancer Lett

  72. OH JH, Lee JY, Kim KH, Kim CY, et al
    Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer.
    Cancer Lett. 2020;495:145-155.
    PubMed         Abstract available


    Cancer Res

  73. BRINKER AE, Vivian CJ, Beadnell TC, Koestler DC, et al
    Mitochondrial Haplotype of the Host Stromal Microenvironment Alters Metastasis in a Non-cell Autonomous Manner.
    Cancer Res. 2020;80:1118-1129.
    PubMed         Abstract available

  74. KARKI K, Wright GA, Mohankumar K, Jin UH, et al
    A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity.
    Cancer Res. 2020;80:1011-1023.
    PubMed         Abstract available

  75. SAMI E, Paul BT, Koziol JA, ElShamy WM, et al
    The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.
    Cancer Res. 2020;80:1102-1117.
    PubMed         Abstract available

  76. BOLKESTEIN M, Wong JKL, Thewes V, Korber V, et al
    Chromothripsis in human breast cancer.
    Cancer Res. 2020 Sep 24. pii: 0008-5472.CAN-20-1920.
    PubMed         Abstract available

  77. DWANE L, O'Connor AE, Das S, Moran B, et al
    A functional genomic screen identifies the deubiquitinase USP11 as a novel transcriptional regulator of ERalpha in breast cancer.
    Cancer Res. 2020 Oct 1. pii: 0008-5472.CAN-20-0214.
    PubMed         Abstract available


    Clin Breast Cancer

  78. COCO S, Boccardo S, Mora M, Fontana V, et al
    Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer.
    Clin Breast Cancer. 2020 Sep 6. pii: S1526-8209(20)30216.
    PubMed         Abstract available


    Clin Cancer Res


  79. Selected Articles from This Issue.
    Clin Cancer Res. 2020;26:323.
    PubMed        

  80. HUTCHINSON KE, Yost SE, Chang CW, Johnson RM, et al
    Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.
    Clin Cancer Res. 2020;26:657-668.
    PubMed         Abstract available

  81. SHEE K, Wells JD, Ung M, Hampsch RA, et al
    A transcriptionally-definable subgroup of triple-negative breast and ovarian cancer samples shows sensitivity to HSP90 inhibition.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-18-2213.
    PubMed         Abstract available

  82. KROP I, Abramson VG, Colleoni M, Traina TA, et al
    A Randomized Placebo-Controlled Phase 2 Trial Evaluating Exemestane With or Without Enzalutamide in Patients With Hormone Receptor-positive Breast Cancer.
    Clin Cancer Res. 2020 Sep 28. pii: 1078-0432.CCR-20-1693.
    PubMed         Abstract available

  83. BARDIA A, Modi S, Oliveira M, Cortes J, et al
    Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer.
    Clin Cancer Res. 2020 Sep 30. pii: 1078-0432.CCR-20-1068.
    PubMed         Abstract available

  84. SCHROTH W, Buttner FA, Kandabarau S, Hoppe R, et al
    Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients.
    Clin Cancer Res. 2020 Oct 2. pii: 1078-0432.CCR-20-1923.
    PubMed         Abstract available


    Clin Med Insights Oncol

  85. LEE JS, Toktas O, Soran A
    Role of Locoregional Treatment in De Novo Stage IV Breast Cancer.
    Clin Med Insights Oncol. 2020;14:1179554920942440.
    PubMed         Abstract available


    Eur J Cancer

  86. SALVADOR-COLOMA C, Santaballa A, Sanmartin E, Calvo D, et al
    Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Eur J Cancer. 2020;139:119-134.
    PubMed         Abstract available


    Eur Radiol

  87. ZHANG Y, Chen JH, Lin Y, Chan S, et al
    Prediction of breast cancer molecular subtypes on DCE-MRI using convolutional neural network with transfer learning between two centers.
    Eur Radiol. 2020 Oct 1. pii: 10.1007/s00330-020-07274.
    PubMed         Abstract available

  88. BLANKS RG, Wallis MG, Alison RJ, Given-Wilson RM, et al
    An analysis of screen-detected invasive cancers by grade in the English breast cancer screening programme: are we failing to detect sufficient small grade 3 cancers?
    Eur Radiol. 2020 Sep 30. pii: 10.1007/s00330-020-07276.
    PubMed         Abstract available

  89. MA L, Lin X, Lai B, Wang W, et al
    Additive value of exposure parameters for breast cancer diagnosis in digital mammography.
    Eur Radiol. 2020 Sep 26. pii: 10.1007/s00330-020-07311.
    PubMed         Abstract available

  90. HOVDA T, Tsuruda K, Hoff SR, Sahlberg KK, et al
    Radiological review of prior screening mammograms of screen-detected breast cancer.
    Eur Radiol. 2020 Oct 1. pii: 10.1007/s00330-020-07130.
    PubMed         Abstract available


    Exp Cell Res

  91. DIMRI S, Malhotra R, Shet T, Mokal S, et al
    Noncanonical pS727 post translational modification dictates major STAT3 activation and downstream functions in breast cancer.
    Exp Cell Res. 2020 Sep 28:112313. doi: 10.1016/j.yexcr.2020.112313.
    PubMed         Abstract available


    Gene

  92. KANUMURI R, Saravanan R, Pavithra V, Sundaram S, et al
    Current trends and opportunities in targeting p21 activated kinase-1(PAK1) for therapeutic management of breast cancers.
    Gene. 2020;760:144991.
    PubMed         Abstract available


    Int J Cancer

  93. TAN PS, Alsheh Ali M, Eriksson M, Hall P, et al
    Mammography features for early markers of aggressive breast cancer subtypes and tumor characteristics - a population-based cohort study.
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33309.
    PubMed         Abstract available

  94. WEITZER J, Castano-Vinyals G, Aragones N, Gomez-Acebo I, et al
    Effect of time of day of recreational and household physical activity on prostate and breast cancer risk (MCC-Spain Study).
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33310.
    PubMed         Abstract available

  95. KINLEN LJ, Gilham C, Ray R, Thomas DB, et al
    Cohabitation, infection and breast cancer risk.
    Int J Cancer. 2020 Sep 27. doi: 10.1002/ijc.33319.
    PubMed         Abstract available


    J Clin Invest

  96. FANG Y, Wang L, Wan C, Sun Y, et al
    MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation.
    J Clin Invest. 2020 Sep 29. pii: 140837. doi: 10.1172/JCI140837.
    PubMed         Abstract available


    J Natl Cancer Inst


  97. Correction: Genetic Factors, Adherence to Healthy Lifestyle Behavior, and Risk of Invasive Breast Cancer Among Women in the UK Biobank.
    J Natl Cancer Inst. 2020 Sep 15. pii: 5906112. doi: 10.1093.
    PubMed        

  98. ALBAIN KS, Gray RJ, Makower DF, Faghih A, et al
    Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial.
    J Natl Cancer Inst. 2020 Sep 28. pii: 5912534. doi: 10.1093.
    PubMed         Abstract available

  99. ZAHL PH
    RE: Breast cancer mortality after implementation of organized population-based screening in Norway.
    J Natl Cancer Inst. 2020 Sep 28. pii: 5912532. doi: 10.1093.
    PubMed        

  100. DIGNAM JJ
    Disparities in Breast Cancer: Narrowing the Gap.
    J Natl Cancer Inst. 2020 Sep 28. pii: 5912531. doi: 10.1093.
    PubMed        


    J Surg Oncol

  101. ESGUEVA A, Siso C, Espinosa-Bravo M, Sobrido C, et al
    Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments.
    J Surg Oncol. 2020 Oct 1. doi: 10.1002/jso.26236.
    PubMed         Abstract available

  102. LEITE FPM, Curi C, Sanches SM, Curado MP, et al
    How to maintain elective treatment of breast cancer during the COVID-19 pandemic-A cancer center experience.
    J Surg Oncol. 2020 Sep 28. doi: 10.1002/jso.26233.
    PubMed        


    Lancet Oncol

  103. HSU A, Matera R, Dizon DS
    Stewart-Treves syndrome: a rapidly fatal complication of breast cancer treatment.
    Lancet Oncol. 2020;21:e495.
    PubMed        

  104. EMENS LA, Esteva FJ, Beresford M, Saura C, et al
    Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
    Lancet Oncol. 2020;21:1283-1295.
    PubMed         Abstract available


    Oncogene

  105. ZHU J, Li X, Su P, Xue M, et al
    The ubiquitin ligase RNF181 stabilizes ERalpha and modulates breast cancer progression.
    Oncogene. 2020 Sep 24. pii: 10.1038/s41388-020-01464.
    PubMed         Abstract available

  106. WANG G, Wang J, Chang A, Cheng D, et al
    Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01481.
    PubMed         Abstract available


    Oncol Rep

  107. YANG B, Shi J, Sun Z, Zhu D, et al
    Attenuated measles virus overcomes radio and chemoresistance in human breast cancer cells by inhibiting the nonhomologous end joining pathway.
    Oncol Rep. 2020;44:2253-2264.
    PubMed         Abstract available

  108. ZHANG Q, Lei L, Jing D
    Knockdown of SERPINE1 reverses resistance of triplenegative breast cancer to paclitaxel via suppression of VEGFA.
    Oncol Rep. 2020;44:1875-1884.
    PubMed         Abstract available

  109. INAGAKI Y, Wu D, Fujiwara K, Ishizuka Y, et al
    Knockdown of E2F5 induces cell death via the TP53dependent pathway in breast cancer cells carrying wildtype TP53.
    Oncol Rep. 2020;44:2241-2252.
    PubMed         Abstract available


    Oncology

  110. BORREANI C, Alfieri S, Infante G, Miceli R, et al
    Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters.
    Oncology. 2020 Sep 29:1-12. doi: 10.1159/000509651.
    PubMed         Abstract available


    PLoS Med

  111. ZIVANOVIC BUJAK A, Weng CF, Silva MJ, Yeung M, et al
    Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    PLoS Med. 2020;17:e1003363.
    PubMed         Abstract available


    PLoS One

  112. GUO A, Drake BF, Khan YM, Langabeer Ii JR, et al
    Time-series cardiovascular risk factors and receipt of screening for breast, cervical, and colon cancer: The Guideline Advantage.
    PLoS One. 2020;15:e0236836.
    PubMed         Abstract available

  113. HARATI R, Hafezi S, Mabondzo A, Tlili A, et al
    Silencing miR-202-3p increases MMP-1 and promotes a brain invasive phenotype in metastatic breast cancer cells.
    PLoS One. 2020;15:e0239292.
    PubMed         Abstract available

  114. LELLUPITIYAGE DON SS, Robertson KL, Lin HH, Labriola C, et al
    Nobiletin affects circadian rhythms and oncogenic characteristics in a cell-dependent manner.
    PLoS One. 2020;15:e0236315.
    PubMed         Abstract available

  115. ROSEN S, Brisson BK, Durham AC, Munroe CM, et al
    Intratumoral collagen signatures predict clinical outcomes in feline mammary carcinoma.
    PLoS One. 2020;15:e0236516.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  116. GRAVES JD, Lee YJ, Liu K, Li G, et al
    E2F1 sumoylation as a protective cellular mechanism in oxidative stress response.
    Proc Natl Acad Sci U S A. 2020;117:14958-14969.
    PubMed         Abstract available


    Radiother Oncol

  117. LOAP P, Tkatchenko N, Nicolas E, Fourquet A, et al
    Optimization and auto-segmentation of a high risk cardiac zone for heart sparing in breast cancer radiotherapy.
    Radiother Oncol. 2020 Sep 29. pii: S0167-8140(20)30819.
    PubMed         Abstract available

  118. CHOI MS, Choi BS, Chung SY, Kim N, et al
    Clinical evaluation of atlas- and deep learning-based automatic segmentation of multiple organs and clinical target volumes for breast cancer.
    Radiother Oncol. 2020 Sep 26. pii: S0167-8140(20)30820.
    PubMed         Abstract available

  119. HYE CHOI K, Ja Ahn S, Uk Jeong J, Yu M, et al
    Postoperative radiotherapy with intensity-modulated radiation therapy versus 3-dimensional conformal radiotherapy in early breast cancer: A randomized clinical trial of KROG 15-03.
    Radiother Oncol. 2020 Sep 24. pii: S0167-8140(20)30818.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: